| Manufacturer ▼ | Drug Name | Indication | Stage | Status | Route of Administration | Drug Class |
|---|---|---|---|---|---|---|
| Sanofi | Amlitelimab (KY1005) - (STREAM-AD) | Atopic dermatitis | Phase 3 | Ongoing | Intravenous | Immunology |
| Sanofi | Eclitasertib (DNL758/SAR443122) | Ulcerative colitis (UC) | Phase 3 | Ongoing | Oral | Gastroenterology |
| Sanofi | Eclitasertib (DNL758/SAR443122) | Ulcerative colitis (UC) | Phase 3 | Ongoing | Oral | Gastroenterology |
| Sanofi | VAT0002 (booster) | COVID-19 vaccine | Phase 3 | Ongoing | Intramuscular | COVID-19 |
| Sanofi | VAT0002 (booster) | COVID-19 vaccine | Phase 3 | Ongoing | Intramuscular | COVID-19 |
| Sanofi | Amcenestrant - (AMEERA-5) | ER+/HER2- advanced breast cancer | Phase 3 | Trial Discontinued | Oral | Oncology |
| Sanofi | LIBTAYO (cemiplimab) | Non-small cell lung cancer (NSCLC) | Phase 3 | Trial Discontinued | intravenous | Oncology |
| Sanofi | PRV-031 (teplizumab) - (PROTECT) | Recent Onset Type 1 Diabetes | Phase 3 | Ongoing | Intravenous | Endocrinology |